Business news for Mon, 31 Dec 2007 & with word review. 11 news.

When I sat down for my annual review of what I've written over the past year, something jumped out at me. Usually, I write about widely diversified subjects. But in 2007, I devoted an inordinate number of columns to the shenanigans of leveraged buyout firms and the attempts by the world's central banks to rescue financial markets.

Starting Jan. 1, customers with complaints against design professionals, from architects to landscape engineers, must first submit their claims to the Hawaii Department of Commerce and Consumer Affairs.

Standard & Poor's gave Hawaii bonds an AA rating in its latest review, citing the state's financial performance and reserves.

NEW YORK (MarketWatch) -- IDM Pharma Inc. said Monday that Sanofi-Aventis has decided to stop participating in the development of investigational melanoma therapy Uvidem. As a result, IDM Pharma, an Irvine, Calif.-based biotechnology company, said it expects to restructure, cut its workforce and review the assets and costs associated with products under development. The board is expected to approve the final restructuring plan during the first quarter of 2008. Shares of IDM Pharma closed Friday at 94 cents.

Our forward-thinking market watcher pens his 2008 year in review a year in advance.

With increasing competition as TV makers slash prices, this model is no bargain considering what you get in terms of performance.

The Samsung BlackJack II not only features a revamped design, but there's been work done under the hood to solve some of the performance issues of the past.

The new Australian government considers the F/A-18E Super Hornet not good enough to guarantee air supremacy for Australia in a region where advanced Su-27 and Mig-29 derivatives are becoming common. But Australia is not exactly spoilt for choice.

Australia will review its air-combat spending program, which includes a $5.8 billion deal for 24 F/A-18 Super Hornet fighter bombers from...

In 2007, we became all too familiar with the undecipherable jargon of the credit market. Alistair Osborne looks back with his alphabetical Year Review.

The New Year heralds a fresh beginning when we can start over and put yesterday's wrongs right. And the extraordinary past 12 months in personal finance have certainly given many of us good reason to review our actions, writes Paul Farrow.